Indication
Seborrheic Dermatitis
6 clinical trials
8 products
Product
RoflumilastProduct
Vehicle FoamClinical trial
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic DermatitisStatus: Completed, Estimated PCD: 2022-04-06
Product
Vehicle foamClinical trial
A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic DermatitisStatus: Completed, Estimated PCD: 2020-08-18
Product
ARQ-154Clinical trial
A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects With Seborrheic DermatitisStatus: Completed, Estimated PCD: 2022-11-19
Clinical trial
Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing ExacerbationStatus: Terminated, Estimated PCD: 2012-02-01
Product
Petroleum JellyClinical trial
PDE4 Inhibition in the Treatment of Seborrheic Dermatitis and Papulopustular Rosacea With PF-07038124Status: Recruiting, Estimated PCD: 2024-12-31
Product
PF-07038124Product
PlaceboClinical trial
Characterizing the Molecular Cutaneous Phenotype of Seborrheic Dermatitis and Treatment Response to Ruxolitinib 1.5% CreamStatus: Completed, Estimated PCD: 2024-01-26
Product
Ruxolitinib